Multi-Center Study Protocol: Impact of Sarcopenia in Early-Onset Colorectal Cancer.
Launched by INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA · Mar 5, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
As reported by the GLOBOCAN study, EOCRC occurs in individuals younger than 50 years old. According to the GLOBOCAN estimates, there were 188,069 new cases of EOCRC, with an Age Standardized Incidence Rate (ASRs) of 2.9 per 100,000 person-years worldwide. Recent evidence suggested an increasing incidence rate for EOCRC in different populations, with greater changes in both developed and developing countries. Despite the declining trend in the incidence of CRC in the total population of the developed countries, the incidence rates for EOCRC were increasing both in the developed and developin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed EOCRC
- • Emergency room access for suspected surgical pathology
- • Age: 18-49 years at diagnosis.
- • Available baseline CT or MRI scans for sarcopenia assessment
- Exclusion Criteria:
- • Presence of comorbidity conditions severely affecting muscle mass unrelated to cancer (e.g., neuromuscular disorders).
- • Inadequate follow-up data or loss to follow-up
- • No past oncological history
About Instituto De Investigación Biomédica De Salamanca
The Instituto de Investigación Biomédica de Salamanca (IBSAL) is a leading biomedical research institution dedicated to advancing healthcare through innovative scientific inquiry and clinical trials. Situated in Salamanca, Spain, IBSAL fosters collaboration among researchers, healthcare professionals, and academic institutions to facilitate cutting-edge research in various medical fields. With a strong emphasis on translational medicine, IBSAL aims to bridge the gap between laboratory discoveries and clinical applications, ultimately enhancing patient care and treatment outcomes. The institute adheres to the highest ethical standards and regulatory compliance, ensuring the integrity and reliability of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported